Cure My Disease

Don't miss your cure!

 Log in / Sign up

Can a light-based blood filter calm immune side effects that steroids can't?

NCT ID NCT05700565

Disease control Sponsor: Lucie Heinzerling Source: ClinicalTrials.gov ↗

What the study statuses mean

This study's is highlighted.

Recruitment status, easiest to join first

Recruiting now
This trial is taking on new participants right now.
Not yet recruiting
Registered, but not yet taking participants.
By invitation only
Not open to general applications. Only people the study team invites can take part.
Paused
Paused for now. It may or may not start again.
Ongoing
Running, but no longer taking on new participants.
Completed This study
The trial has finished. Results may not be published yet.
Stopped early
Stopped early, before it reached the end. That can be for many reasons, including safety.
Cancelled
Cancelled before anyone took part.

Expanded access (not trials)

Expanded access
Not a trial. This treatment can be requested outside a study, case by case, for people who qualify.
Expanded access (paused)
Not a trial. The treatment can normally be requested outside a study, but is unavailable right now.
Expanded access (ended)
Not a trial. The treatment could once be requested outside a study, but no longer can.
Approved
The treatment has been approved, so it is available normally rather than through this programme.

When the status isn't known

Details not published
The full record has not been published yet, so there is little to show here.
Status unknown
This status has not been confirmed recently, so it may be out of date.

First seen Sep 08, 2026 · Last updated Sep 09, 2026 · Updated 1 time

Summary

This trial tests whether a procedure called extracorporeal photopheresis (ECP) can help people whose immune-related side effects from cancer immunotherapy do not improve with standard steroid treatment. ECP involves removing blood, treating it with light, and returning it to the body to calm the immune system. Participants receive either ECP or another immunosuppressive drug chosen by their doctor, and researchers track side effect severity, quality of life, and immune cell changes over 24 weeks.

What this could mean

Our plain-language read of the trial. This is informational only, not medical advice or a prediction.

Active substance
Extracorporeal photopheresis (ECP), a procedure where blood is treated with light and returned to the body, or other immunosuppressive drugs
What this could lead to
If ECP works, it could offer a new way to calm severe immune-related side effects from cancer immunotherapy when steroids fail, helping patients stay on treatment.
What could go wrong
This is a small, early study, and ECP may not improve symptoms for everyone. The procedure carries risks like infection or bleeding, and results may not apply broadly.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Study facts

What this study's own registry entry says, in plain language.

Participants

46 people

The number who actually took part.

Started

Jan 2022

Finished

Oct 2025

Lead sponsor

Other sponsor

The registry's catch-all category, for sponsors it does not file as a company, a government agency, or a research network.

Who can take part

This study's own entry requirements. Only the study team can say for certain whether you qualify.

Who is studied

Patients with irAE after immune checkpoint inhibitor therapy (PD-1/PD-L1 or PD-1 + CTLA4 blockade) refractory to therapy with corticosteroids or inability to taper corticosteroids to prednisone equivalent \<= 5mg. An irAE is defined as refractory if corticosteroids do not improve symptoms within 72 hours. The inability to taper corticosteroids is defined as relapse on standard tapering of 1 mg/kg corticosteroid over 28 days.

Ages

Children (under 18), adults (18 to 64) and older adults (65 and over)

Sex

Anyone

Show the full entry requirements

Copied word for word from the study's registry entry, so the wording is the study team's rather than ours.

Inclusion Criteria: 1. Subjects must we willing and able to comply with scheduled visits and must have given written informed consent. 2. irAE after immune checkpoint inhibitor therapy (PD-1/PD-L1 or PD-1 + CTLA4 blockade) 3. irAE refractory to therapy with corticosteroids or inability to taper corticosteroids to prednisone equivalent \<= 5mg. An irAE is defined as refractory if corticosteroids do not improve symptoms within 72 hours. The inability to taper corticosteroids is defined as relapse on standard tapering of 1 mg/kg corticosteroid over 28 days. Exclusion Criteria: 1. Contraindications for the treatment with ECP including a known sensitivity to psoralen compounds such as 8-MOP, comorbidities that may result in photosensitivity, aphakia, history of heparin-induced thrombocytopenia, unsatisfactory cardio-circulatory function, low hematocrit values 2. Pregnancy 3. Body weight less than 40 kg.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for Immune-related adverse event are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

Immune-related adverse event

Contacts and locations

Locations

  • LMU Klinikum Hauttumorzentrum

    Munich, 80337, Germany

More trials for these conditions

Other studies related to the condition(s) this trial covers.